Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that Ewoud Welten, the Company’s Chief Financial Officer (‘CFO’), has decided to resign from Biocartis and to pursue an opportunity in the Netherlands, closer to his home and family.
Biocartis has initiated a selection process to recruit a new CFO. The Company and Mr. Welten have agreed that he will stay with Biocartis until the end of March 2020 to ensure a smooth transition for the Company.
Herman Verrelst, Chief Executive Officer of Biocartis, commented: “Ewoud has been with us for around 5 years and during this time he has been a valuable asset to the company. He was instrumental in securing the necessary financing for the Company and leaves behind strong teams in finance, legal and investor relations ready to support the Company’s ambitious growth plans for the next years. I am sorry to see him go but respect his decision. We wish him all the best.”
About Biocartis
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs in oncology. This represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer. More information: www.biocartis.com. Follow us on Twitter: @Biocartis_.
Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla™ trademark and logo are used trademarks owned by Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.